Chamaria, Surbhi
Johnson, Kipp W. http://orcid.org/0000-0002-5102-741X
Vengrenyuk, Yuliya
Baber, Usman
Shameer, Khader
Divaraniya, Aparna A.
Glicksberg, Benjamin S. http://orcid.org/0000-0003-4515-8090
Li, Li
Bhatheja, Samit
Moreno, Pedro
Maehara, Akiko
Mehran, Roxana
Dudley, Joel T.
Narula, Jagat
Sharma, Samin K.
Kini, Annapoorna S.
Article History
Received: 17 March 2017
Accepted: 20 June 2017
First Online: 1 August 2017
Competing Interests
: Dr. Roxana Mehran has received financial compensation as a consultant and lecturer for AstraZeneca in 2014. Dr. Pedro Moreno is a co-Founder of InfraReDx, Inc. and is named under the first patent for LipiScanTM NIR Coronary Imaging System (near infrared spectroscopy, or NIRS) marketed by InfraReDx; he also owns equity in InfraReDx in the form of stock options. NIRS imaging technology was utilized in this study for the detection of lipid rich plaques. Dr. Moreno has also received financial compensation as a speaker for AstraZeneca. Dr. Dudley has received consulting fees or honoraria from Janssen Pharmaceuticals, GlaxoSmithKline, AstraZeneca, and Hoffman-La Roche; is a scientific advisor to LAM Therapeutics; and holds equity in NuMedii Inc., Ayasdi Inc., and Ontomics, Inc. Other investigators have reported no financial conflict of interest.